- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Extended-release Naltrexone proves beneficial in Alcohol Use Disorder: Study
U.S.A : Initiating Alcohol Use Disorder therapy with XR-naltrexone and case management in an ED setting is achievable, according to a study published in Annals of Emergency Medicine.
At any given moment, 7 to 8% of the population, or roughly 15 to 20 million persons, are affected by alcohol use disorders, including alcohol abuse and dependence. According to the World Health Organization, the third most common source of disease burden in developing nations worldwide is alcohol dependence. Agents such as naltrexone inhibit opioid receptors, especially the μ-opioid receptor. Naltrexone has also been proven to reduce alcohol usage in clinical laboratory settings.
The main objective of the study was to evaluate the viability of starting treatment for alcohol use disorder in the emergency department (ED) with extended-release naltrexone (XR-Naltrexone) and case management services, as well as to calculate the intervention's effects on daily alcohol consumption (DAC) and quality of life (QOL).
For this purpose, a 12-week prospective open-label single-arm research was started at a single metropolitan academic ED using a multimodal approach to treating alcohol dependence that included monthly XR-naltrexone injections and case management services. Participants were adult ED patients who were actively drinking and had a AUDIT-C score of greater than 4. 179 patients were approached and 32 enrolled (18%). The percentages of participants who enrolled/approached, completed/enrolled, and continued naltrexone beyond the trial/were enrolled were the major feasibility outcomes. The 14-day timeline follow back was used to quantify the change in DAC (drinks/day, 14g ethanol/drink), and the single-item Kemp QOL scale was used to measure the change in QOL.
Key findings of the trial:
- 25/32 (78%) of the participants finished the study; 22/32 (69%) remained taking naltrexone.
- On a scale of 1 to 7, the baseline DAC was 7.6 drinks per day (IQR 4.5 to 13.4), while the mean QOL was 3.6 (SD 1.7).
- After 12 weeks of therapy, the median daily alcohol consumption (DAC) change was -7.5 (Hodges-Lehman 95% CI -8.6, -5.9).
- The average change in QOL was 1.2 points (95% CI: 0.5 to 1.9; P < 0.01).
The authors concluded that this treatment has been shown to significantly reduce drinking and enhance quality of life over the short term and to further validate these findings, multi-center RCTs are required.
REFERENCE
C. Murphy ,R. Wang, J.C. Montoy,Z. Coralic, B. Ramirez,M. Raven; 6 Extended-release Naltrexone and Case Management for Treatment of Alcohol Used Disorder in the Emergency Department; https://doi.org/10.1016/j.annemergmed.2022.08.028; VOLUME 80, ISSUE 4, SUPPLEMENT , S3, OCTOBER 01, 2022.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751